{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-21-000168","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2021-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.448419+00:00","generated_at":"2026-06-29T23:34:31.634524+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lilly Q2 revenue $6.74B (+23% YoY); non-GAAP EPS $1.87 (+29%); updates 2021 guidance","bullets":["Revenue $6.74B (+23% YoY); volume growth 22%; non-GAAP EPS $1.87 (+29% YoY).","Reported EPS $1.53 (-1% YoY) due to $423M COVID antibody inventory charge.","2021 GAAP EPS guidance updated to $6.73-$6.93; non-GAAP unchanged at $7.80-$8.00.","Key products: Trulicity +25%, Taltz +44%, Verzenio +64%; pipeline milestones for tirzepatide, Jardiance, donanemab.","Board authorizes $5B share repurchase; acquires Protomer; global collaboration with MiNA."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-21-000168","json":"https://secwatch.observer/filing/0000059478-21-000168.json","markdown":"https://secwatch.observer/filing/0000059478-21-000168.md","text":"https://secwatch.observer/filing/0000059478-21-000168.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947821000168/0000059478-21-000168-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947821000168/lly-20210803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T23:34:31.634524+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}